Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

PEPG

PepGen Inc

Jun 13 • 12:06PM ET

17.35

Dollar change -0.36
Percentage change -2.03	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO IWO IWC AVSC IWV RYLD

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.25	Insider Own	20.88%	Shs Outstand	32.42M	Perf Week	0.06%
Market Cap	562.49M	Forward P/E	-	EPS next Y	-2.78	Insider Trans	60.02%	Shs Float	25.65M	Perf Month	24.02%
Income	-80.33M	PEG	-	EPS next Q	-0.72	Inst Own	70.01%	Short Float	1.54%	Perf Quarter	24.73%
Sales	0.00M	P/S	-	EPS this Y	13.20%	Inst Trans	-0.43%	Short Ratio	5.30	Perf Half Y	147.15%
Book/sh	5.53	P/B	3.14	EPS next Y	2.92%	ROA	-39.37%	Short Interest	0.39M	Perf Year	30.84%
Cash/sh	5.40	P/C	3.21	EPS next 5Y	-	ROE	-46.72%	52W Range	3.72 - 18.38	Perf YTD	155.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-172.30%	ROI	-41.04%	52W High	-5.60%	Beta	1.77
Dividend TTM	-	Quick Ratio	15.78	Sales past 5Y	0.00%	Gross Margin	-	52W Low	366.40%	ATR (14)	1.25
Dividend Ex-Date	-	Current Ratio	15.78	EPS Y/Y TTM	2.65%	Oper. Margin	0.00%	RSI (14)	60.63	Volatility	7.01% 8.55%
Employees	64	Debt/Eq	0.11	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	21.60
Option/Short	No / Yes	LT Debt/Eq	0.09	EPS Q/Q	8.44%	Payout	-	Rel Volume	0.20	Prev Close	17.71
Sales Surprise	-	EPS Surprise	18.85%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	74.32K	Price	17.35
SMA20	10.98%	SMA50	25.87%	SMA200	80.66%	Trades		Volume	6,543	Change	-2.03%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-21-22	Initiated	H.C. Wainwright	Buy	$26

Jun-11-24 07:00AM	PepGen Announces Executive Team Promotions (Business Wire)
May-15-24 01:20PM	PepGen Q1 Loss Narrows (MT Newswires)
May-14-24 10:55PM	PEPG Stock Earnings: PepGen Beats EPS for Q1 2024 (InvestorPlace) +5.19%
04:02PM	PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Apr-12-24 01:30PM	Hedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and More (Insider Monkey)
04:05PM	Loading…
Mar-13-24 04:05PM	PepGen to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:00AM	PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-12-24 09:55AM	Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect? (Zacks)
Mar-11-24 12:00PM	PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-06-24 11:54PM	PEPG Stock Earnings: PepGen Beats EPS for Q4 2023 (InvestorPlace) -7.34%
04:01PM	PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Mar-04-24 07:00AM	PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) +14.68%
Feb-20-24 08:00AM	PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Feb-07-24 07:30AM	PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock (GlobeNewswire) +17.63%
07:00AM	Loading…
Jan-17-24 07:00AM	Mary Beth DeLena Joins PepGen as General Counsel and Secretary (GlobeNewswire)
Jan-08-24 07:00AM	PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping (GlobeNewswire)
Dec-18-23 08:00AM	PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +6.03%
Nov-15-23 08:00AM	PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors (GlobeNewswire)
Nov-08-23 08:00AM	PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire) -10.40%
Oct-12-23 07:00AM	PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +7.22%
Sep-27-23 04:16PM	PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology (GlobeNewswire)
Sep-06-23 04:05PM	PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1 (GlobeNewswire)
08:00AM	PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Companys Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences (GlobeNewswire)
Sep-01-23 08:00AM	PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-08-23 08:15AM	PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Jun-13-23 04:05PM	PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1 (GlobeNewswire) +10.87%
May-31-23 11:44AM	PepGen (PEPG) Down on Clinical Hold for DM1 Candidate (Zacks) -5.07%
May-30-23 04:05PM	PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
May-18-23 07:00AM	PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
07:00AM	Loading…
May-11-23 07:00AM	PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
May-04-23 08:00AM	PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference (GlobeNewswire)
Apr-17-23 08:00AM	PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting (GlobeNewswire) +23.09%
Apr-13-23 04:05PM	PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +6.07%
Mar-27-23 02:25AM	PepGen Inc. (NASDAQ:PEPG) Q4 2022 Earnings Call Transcript (Insider Monkey) -16.15%
Mar-23-23 04:05PM	PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments (GlobeNewswire)
Mar-22-23 08:00AM	PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference (GlobeNewswire)
Mar-21-23 04:05PM	PepGen to Participate in the Stifel 2023 CNS Days Conference (GlobeNewswire)
Mar-16-23 08:00AM	PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call (GlobeNewswire) +6.99%
Mar-13-23 08:00AM	PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference (GlobeNewswire)
Feb-27-23 08:50AM	PepGen, Inc. (PEPG) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -6.02%
Feb-09-23 08:00AM	PepGen to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire) -5.07%
Jan-31-23 08:50AM	Here's Why Momentum in PepGen, Inc. (PEPG) Should Keep going (Zacks)
Jan-16-23 05:10AM	Companies Like PepGen (NASDAQ:PEPG) Are In A Position To Invest In Growth (Simply Wall St.)
Jan-13-23 08:50AM	Here's What Could Help PepGen, Inc. (PEPG) Maintain Its Recent Price Strength (Zacks)
Dec-21-22 02:25PM	Why This PepGen Analyst Is Bullish On The Biotech Stock (Benzinga)
Dec-07-22 08:00AM	PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies (GlobeNewswire)
Dec-01-22 09:55AM	Wall Street Analysts See a 50% Upside in PepGen, Inc. (PEPG): Can the Stock Really Move This High? (Zacks) -6.42%
Nov-21-22 08:50AM	What Makes PepGen, Inc. (PEPG) a Good Fit for 'Trend Investing' (Zacks) +5.54%
Nov-15-22 09:55AM	Wall Street Analysts Predict a 68% Upside in PepGen, Inc. (PEPG): Here's What You Should Know (Zacks)
Nov-14-22 08:00AM	PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates (GlobeNewswire) +8.33%
Nov-10-22 08:00AM	PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) +12.92%
Nov-08-22 08:00AM	PepGen to Participate in the Stifel 2022 Healthcare Conference (GlobeNewswire)
Oct-13-22 01:00PM	PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress (GlobeNewswire)
Sep-28-22 01:59PM	PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst (Benzinga) +110.19%
09:25AM	PepGen Touts Encouraging Early-Stage Data From Duchenne Program (Benzinga)
06:00AM	PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-22-22 08:00AM	PepGen Appoints Habib Dable to Board of Directors (GlobeNewswire)
Sep-04-22 07:17AM	3 IPO Stocks to Watch in September (TipRanks)
Aug-12-22 08:00AM	PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) -6.70%
Aug-08-22 10:51AM	We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth (Simply Wall St.)
Jul-22-22 07:45AM	PepGen Appoints Caroline Godfrey, Ph.D. to the Companys Scientific Advisory Board (GlobeNewswire)
Jun-16-22 08:30AM	PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) +12.70%
May-27-22 05:22PM	Covetrus and PepGen Stock See Action From Activist Investors (Barrons.com) +5.63%
May-05-22 11:34PM	PepGen Announces Pricing of Initial Public Offering (GlobeNewswire)

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mellion Michelle L	SVP, Clinical Development	Jun 06 '24	Option Exercise	10.21	1,411	14,406	1,411	Jun 07 04:12 PM
Mellion Michelle L	SVP, Clinical Development	Jun 06 '24	Sale	18.00	1,411	25,398	0	Jun 07 04:12 PM
Mellion Michelle L	SVP, Clinical Development	Jun 05 '24	Option Exercise	10.21	7,245	73,971	7,245	Jun 07 04:12 PM
Mellion Michelle L	SVP, Clinical Development	Jun 05 '24	Sale	18.09	7,245	131,062	0	Jun 07 04:12 PM
Svenstrup Niels	SVP, Chem. Mfg & Controls	May 17 '24	Sale	13.41	10,000	134,100	0	May 17 08:51 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 09 '24	Buy	10.64	2,557,593	27,212,790	9,179,273	Feb 13 04:33 PM
McArthur James G	President and CEO	Nov 30 '23	Buy	4.17	1,694	7,056	1,694	Dec 05 07:34 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PEPG

PepGen Inc

Upgrade your FINVIZ experience